Pharmacoepidemiology in Safety Evaluations of Newly Approved Medications

In the recent extension of the Prescription Drug User Fee Act, the risk management programs that are to be funded by additional user fees combine ascertainment of risks in the initial postapproval phase with activities to confront these risks. Better recognition of risks, a prerequisite for success...

Full description

Saved in:
Bibliographic Details
Published in:Drug information journal 2004-01, Vol.38 (1), p.61-67
Main Author: Gutterman, Elane M.
Format: Article
Language:English
Subjects:
Clinical trials
Pharmaceutics
Pharmacoepidemiology
Pharmacology
Pharmacovigilance
Prescription drugs
Regulatory approval
Risk management
Safety
User fees
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c511t-9bf854c3108c0396087c5887ff0142508ed4a540353d993e09a9586912c4586d3
cites cdi_FETCH-LOGICAL-c511t-9bf854c3108c0396087c5887ff0142508ed4a540353d993e09a9586912c4586d3
container_end_page 67
container_issue 1
container_start_page 61
container_title Drug information journal
container_volume 38
creator Gutterman, Elane M.
description In the recent extension of the Prescription Drug User Fee Act, the risk management programs that are to be funded by additional user fees combine ascertainment of risks in the initial postapproval phase with activities to confront these risks. Better recognition of risks, a prerequisite for success in managing risks, will require strategies to supplement the present system of spontaneous event reporting. This overview considers the merits of pharmacoepidemiology studies in examining gaps in drug safety resulting from the inherent limitations of clinical trials. After drugs become widely used following regulatory approval, many health outcomes potentially related to drug exposures can be studied in large health insurance claims databases using pharmacoepidemiology designs tailored to this venue. We clarify types of safety investigations particularly suited to examination in a large claims database, as well as the benefits and caveats of expanding postapproval follow-up through Prescription Drug User Fee Act funding.
doi_str_mv 10.1177/009286150403800109
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_275126217</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_009286150403800109</sage_id><sourcerecordid>2450778473</sourcerecordid><originalsourceid>FETCH-LOGICAL-c511t-9bf854c3108c0396087c5887ff0142508ed4a540353d993e09a9586912c4586d3</originalsourceid><addsrcrecordid>eNp9kV9LwzAUxYMoOOa-gE9Fwbe5mzRpkscxphPmH1CfS0yT2dE2tWkn_fZmVBEUvS_3wv2dw7lchE4xXGLM-QxAEpFgBhRiAYBBHqARwYmYUgH08GvmEo7RxPsthJKCcSJGaPXwqppSaWfqPDNl7gq36aO8ih6VNW0fLXeq6FSbu8pHzkZ35r3oo3ldN25nsujWZLketifoyKrCm8lnH6Pnq-XTYjVd31_fLObrqWYYt1P5YgWjOsYgNMQyAcE1E4JbC5gSBsJkVLFwCIszKWMDUkkmEomJpqFn8RhdDL4hwltnfJuWudemKFRlXOdTxpnkDMcBPPsBbl3XVCFbSgJAEoJ5gM7_hCgDzgXleysyULpx3jfGpnWTl6rpUwzp_gXp7xcE0WwQebUx37b_KD4Ay4KC2g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>275126217</pqid></control><display><type>article</type><title>Pharmacoepidemiology in Safety Evaluations of Newly Approved Medications</title><source>Library &amp; Information Science Abstracts (LISA)</source><source>Springer Nature</source><creator>Gutterman, Elane M.</creator><creatorcontrib>Gutterman, Elane M.</creatorcontrib><description>In the recent extension of the Prescription Drug User Fee Act, the risk management programs that are to be funded by additional user fees combine ascertainment of risks in the initial postapproval phase with activities to confront these risks. Better recognition of risks, a prerequisite for success in managing risks, will require strategies to supplement the present system of spontaneous event reporting. This overview considers the merits of pharmacoepidemiology studies in examining gaps in drug safety resulting from the inherent limitations of clinical trials. After drugs become widely used following regulatory approval, many health outcomes potentially related to drug exposures can be studied in large health insurance claims databases using pharmacoepidemiology designs tailored to this venue. We clarify types of safety investigations particularly suited to examination in a large claims database, as well as the benefits and caveats of expanding postapproval follow-up through Prescription Drug User Fee Act funding.</description><identifier>ISSN: 2168-4790</identifier><identifier>ISSN: 0092-8615</identifier><identifier>EISSN: 2168-4804</identifier><identifier>EISSN: 2164-9200</identifier><identifier>DOI: 10.1177/009286150403800109</identifier><identifier>CODEN: DGIJB9</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Clinical trials ; Pharmaceutics ; Pharmacoepidemiology ; Pharmacology ; Pharmacovigilance ; Prescription drugs ; Regulatory approval ; Risk management ; Safety ; User fees</subject><ispartof>Drug information journal, 2004-01, Vol.38 (1), p.61-67</ispartof><rights>2004 Drug Information Association</rights><rights>Drug Information Association, Inc 2004.</rights><rights>Copyright Drug Information Association 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c511t-9bf854c3108c0396087c5887ff0142508ed4a540353d993e09a9586912c4586d3</citedby><cites>FETCH-LOGICAL-c511t-9bf854c3108c0396087c5887ff0142508ed4a540353d993e09a9586912c4586d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,34136</link.rule.ids></links><search><creatorcontrib>Gutterman, Elane M.</creatorcontrib><title>Pharmacoepidemiology in Safety Evaluations of Newly Approved Medications</title><title>Drug information journal</title><description>In the recent extension of the Prescription Drug User Fee Act, the risk management programs that are to be funded by additional user fees combine ascertainment of risks in the initial postapproval phase with activities to confront these risks. Better recognition of risks, a prerequisite for success in managing risks, will require strategies to supplement the present system of spontaneous event reporting. This overview considers the merits of pharmacoepidemiology studies in examining gaps in drug safety resulting from the inherent limitations of clinical trials. After drugs become widely used following regulatory approval, many health outcomes potentially related to drug exposures can be studied in large health insurance claims databases using pharmacoepidemiology designs tailored to this venue. We clarify types of safety investigations particularly suited to examination in a large claims database, as well as the benefits and caveats of expanding postapproval follow-up through Prescription Drug User Fee Act funding.</description><subject>Clinical trials</subject><subject>Pharmaceutics</subject><subject>Pharmacoepidemiology</subject><subject>Pharmacology</subject><subject>Pharmacovigilance</subject><subject>Prescription drugs</subject><subject>Regulatory approval</subject><subject>Risk management</subject><subject>Safety</subject><subject>User fees</subject><issn>2168-4790</issn><issn>0092-8615</issn><issn>2168-4804</issn><issn>2164-9200</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>F2A</sourceid><recordid>eNp9kV9LwzAUxYMoOOa-gE9Fwbe5mzRpkscxphPmH1CfS0yT2dE2tWkn_fZmVBEUvS_3wv2dw7lchE4xXGLM-QxAEpFgBhRiAYBBHqARwYmYUgH08GvmEo7RxPsthJKCcSJGaPXwqppSaWfqPDNl7gq36aO8ih6VNW0fLXeq6FSbu8pHzkZ35r3oo3ldN25nsujWZLketifoyKrCm8lnH6Pnq-XTYjVd31_fLObrqWYYt1P5YgWjOsYgNMQyAcE1E4JbC5gSBsJkVLFwCIszKWMDUkkmEomJpqFn8RhdDL4hwltnfJuWudemKFRlXOdTxpnkDMcBPPsBbl3XVCFbSgJAEoJ5gM7_hCgDzgXleysyULpx3jfGpnWTl6rpUwzp_gXp7xcE0WwQebUx37b_KD4Ay4KC2g</recordid><startdate>200401</startdate><enddate>200401</enddate><creator>Gutterman, Elane M.</creator><general>SAGE Publications</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>S0X</scope><scope>E3H</scope><scope>F2A</scope></search><sort><creationdate>200401</creationdate><title>Pharmacoepidemiology in Safety Evaluations of Newly Approved Medications</title><author>Gutterman, Elane M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c511t-9bf854c3108c0396087c5887ff0142508ed4a540353d993e09a9586912c4586d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Clinical trials</topic><topic>Pharmaceutics</topic><topic>Pharmacoepidemiology</topic><topic>Pharmacology</topic><topic>Pharmacovigilance</topic><topic>Prescription drugs</topic><topic>Regulatory approval</topic><topic>Risk management</topic><topic>Safety</topic><topic>User fees</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gutterman, Elane M.</creatorcontrib><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Proquest Health &amp; Medical Complete</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Research Library</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>Library &amp; Information Sciences Abstracts (LISA)</collection><collection>Library &amp; Information Science Abstracts (LISA)</collection><jtitle>Drug information journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gutterman, Elane M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacoepidemiology in Safety Evaluations of Newly Approved Medications</atitle><jtitle>Drug information journal</jtitle><date>2004-01</date><risdate>2004</risdate><volume>38</volume><issue>1</issue><spage>61</spage><epage>67</epage><pages>61-67</pages><issn>2168-4790</issn><issn>0092-8615</issn><eissn>2168-4804</eissn><eissn>2164-9200</eissn><coden>DGIJB9</coden><abstract>In the recent extension of the Prescription Drug User Fee Act, the risk management programs that are to be funded by additional user fees combine ascertainment of risks in the initial postapproval phase with activities to confront these risks. Better recognition of risks, a prerequisite for success in managing risks, will require strategies to supplement the present system of spontaneous event reporting. This overview considers the merits of pharmacoepidemiology studies in examining gaps in drug safety resulting from the inherent limitations of clinical trials. After drugs become widely used following regulatory approval, many health outcomes potentially related to drug exposures can be studied in large health insurance claims databases using pharmacoepidemiology designs tailored to this venue. We clarify types of safety investigations particularly suited to examination in a large claims database, as well as the benefits and caveats of expanding postapproval follow-up through Prescription Drug User Fee Act funding.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><doi>10.1177/009286150403800109</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 2168-4790
ispartof Drug information journal, 2004-01, Vol.38 (1), p.61-67
issn 2168-4790
0092-8615
2168-4804
2164-9200
language eng
recordid cdi_proquest_journals_275126217
source Library & Information Science Abstracts (LISA); Springer Nature
subjects Clinical trials
Pharmaceutics
Pharmacoepidemiology
Pharmacology
Pharmacovigilance
Prescription drugs
Regulatory approval
Risk management
Safety
User fees
title Pharmacoepidemiology in Safety Evaluations of Newly Approved Medications
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T22%3A41%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacoepidemiology%20in%20Safety%20Evaluations%20of%20Newly%20Approved%20Medications&rft.jtitle=Drug%20information%20journal&rft.au=Gutterman,%20Elane%20M.&rft.date=2004-01&rft.volume=38&rft.issue=1&rft.spage=61&rft.epage=67&rft.pages=61-67&rft.issn=2168-4790&rft.eissn=2168-4804&rft.coden=DGIJB9&rft_id=info:doi/10.1177/009286150403800109&rft_dat=%3Cproquest_cross%3E2450778473%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c511t-9bf854c3108c0396087c5887ff0142508ed4a540353d993e09a9586912c4586d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=275126217&rft_id=info:pmid/&rft_sage_id=10.1177_009286150403800109&rfr_iscdi=true